Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

847742

registered interest
date	23/02/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	HIV Infection: Prisoners
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the (a) availability, (b) quality and (c) effectiveness of HIV testing and treatment in prisons.
tabling member constituency	Bristol West
tabling member printed	Thangam Debbonaire
uin	129418
answer	answer is ministerial correction date of answer 05/03/2018 answer text <p>HIV testing is available in all prisons in England through healthcare services commissioned by NHS England, through both primary care and genitourinary medicine services. Additionally, all adult prisons in England will provide HIV testing through an ‘opt-out’ testing programme at or near reception by the end of the current financial year as part of a wider blood-borne virus opt-out testing programme being delivered in partnership between Public Health England, NHS England and Her Majesty’s Prison and Probation Service.</p><p> </p><p>The quality of services is assessed by NHS England on a quarterly basis through the collection of data via the Health and Justice Indicators of Performance (HJIPs), which includes information on the number of people offered HIV tests, those tested and the number of people newly diagnosed with HIV referred for treatment within two weeks of diagnosis.</p><p> </p><p>For quarter one of financial year 2017/18, 10,574 prisoners were tested for HIV, and 197 cases of HIV were diagnosed in this cohort. Of those, 39 were seen by specialist service providers within two weeks of diagnosis. Further information is available here:</p><p> </p><p><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/666850/BBV_bulletin_Dec_2017.pdf" target="_blank">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/666850/BBV_bulletin_Dec_2017.pdf</a></p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 05/03/2018 14:27:53 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4433 label Biography information for Thangam Debbonaire

847743

registered interest
date	23/02/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Prisons
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the (a) quality, (b) availability and (c) effectiveness of drug treatment services in prisons.
tabling member constituency	Bristol West
tabling member printed	Thangam Debbonaire
uin	129419
answer	answer is ministerial correction date of answer 05/03/2018 answer text <p>Drug treatment services in prisons have been systematically reviewed over the past 18 months, as a part of the development of a new service specification. NHS England and their partners support development of a new commissioning service specification as part of a quality improvement programme for prison health services. The NHS England teams that commission these assessments also hold quarterly performance review meetings with drug treatment providers, and recommission the services as a part of a three to five year cycle (or earlier if required).</p><p> </p><p>On average, there was no wait for drug treatment services and nearly all (95%) people started their first treatment intervention within three weeks of being assessed but would start immediately if it was clinically appropriate to do so. Regular needs assessments are undertaken by NHS England to identify specific establishment-level needs.</p><p> </p><p>Effectiveness is measured by Public Health England through the National Drug Treatment Monitoring System. In total, 37,330 individuals left treatment between 1 April 2016 and 31 March 2017. Of the individuals that left treatment in the year, 10,066 (27%) were discharged as ‘treatment completed’, up from 23% in 2015-16. Further information is available here:</p><p> </p><p><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/677500/OFFICIAL-SENSITIVE_secure_setting_annual_report_2016-17FINAL-v1.2.pdf" target="_blank">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/677500/OFFICIAL-SENSITIVE_secure_setting_annual_report_2016-17FINAL-v1.2.pdf</a></p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 05/03/2018 14:29:11 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4433 label Biography information for Thangam Debbonaire

818982

registered interest
date	09/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Alcoholic Drinks: Labelling
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the likely effects of introducing warnings on alcoholic products at the point of sale on a link between alcohol and cancer and other health matters.
tabling member constituency	Bristol West
tabling member printed	Thangam Debbonaire
uin	121659
answer	answer is ministerial correction date of answer 17/01/2018 answer text <p>Public Health England’s evidence review on the public health burden of alcohol found that alcohol health warning labels on alcoholic products can raise awareness of the messages they contain. However, the evidence review did not identify any studies which considered the specific impact of warnings at the point of sale on the link between alcohol and cancer and other health harms. The review is available at the following link:</p><p><a href="http://www.gov.uk/government/publications/the-public-health-burden-of-alcohol-evidence-review" target="_blank">www.gov.uk/government/publications/the-public-health-burden-of-alcohol-evidence-review</a></p> answering member constituency Winchester answering member printed Steve Brine question first answered 17/01/2018 14:28:32 answering member 4067 label Biography information for Steve Brine
tabling member	4433 label Biography information for Thangam Debbonaire

818990

registered interest
date	09/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Clinical Trials
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will consider the merits of introducing a national audit system for clinical trials; and if he will make a statement.
tabling member constituency	Bristol West
tabling member printed	Thangam Debbonaire
uin	121667
answer	answer is ministerial correction date of answer 17/01/2018 answer text <p><strong></strong>All clinical trials of investigational medicinal products in the European Union are registered and information on the trial and a summary of results is made public in the EU clinical trials register, except for adult phase 1 trials which are considered commercially confidential.</p><p> </p><p>Good clinical practice (GCP) is a set of internationally-recognised ethical and scientific quality requirements that must be followed when designing, conducting, recording and reporting clinical trials that involve people. To ensure compliance with GCP, the Medicines and Healthcare products Regulatory Agency carries out inspections in the United Kingdom of organisations that are involved in clinical trials.</p><p> </p><p>The Government’s National Institute for Health Research (NIHR) which is the country’s largest public funder of health research and trials, has implemented a number of initiatives on publication of research results. The NIHR is the world’s first health research funder to publish comprehensive accounts of its commissioned research within its own publicly and permanently available journal series. The NIHR Journals Library comprises a suite of five open access peer-reviewed journals reporting results from a range of health research areas. The reports provide a full account of the research project, including methods and a full description of the results, and complement shorter articles submitted for publication in other peer-review journals, which the NIHR actively encourages researchers to do as part of their dissemination strategy. In addition – contracts for NIHR funding include requirements on publication of the results from NIHR funded and supported research.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 17/01/2018 14:41:19 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4433 label Biography information for Thangam Debbonaire

818797

registered interest
date	08/01/2018
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Health Services: Refugees
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will publish guidance for healthcare professionals on the entitlements refugees have to NHS treatment.
tabling member constituency	Bristol West
tabling member printed	Thangam Debbonaire
uin	121561
answer	answer is ministerial correction date of answer 11/01/2018 answer text <p>The Department has published extensive guidance on implementing the overseas visitor charging regulations. This guidance is for use by all frontline staff providing National Health Service funded services, as well as the providers and commissioners of those services. It is available at:</p><p><a href="https://www.gov.uk/government/publications/guidance-on-overseas-visitors-hospital-charging-regulations" target="_blank">https://www.gov.uk/government/publications/guidance-on-overseas-visitors-hospital-charging-regulations</a></p><p>This guidance, most recently refreshed in December 2017, is clear that refugees (those granted asylum, humanitarian protection or temporary protection under the immigration rules), and their dependents, are exempt from charges for NHS-funded services. They are therefore eligible for free NHS care in the same way as someone who is ordinarily resident in the United Kingdom. This guidance also sets out that any individual who has made a formal application with the Home Office to be granted asylum, temporary protection or humanitarian protection which has not yet been determined is also exempt from charges, as are their dependants, as part of the application.</p><p> </p><p>Advice and guidance for healthcare practitioners on the health needs of migrant patients, including refugees, was also published by Public Health England on 8 January 2018 and is available at:</p><p><a href="https://www.gov.uk/guidance/nhs-entitlements-migrant-health-guide" target="_blank">https://www.gov.uk/guidance/nhs-entitlements-migrant-health-guide</a></p> answering member constituency North East Cambridgeshire answering member printed Stephen Barclay question first answered 11/01/2018 15:29:58 answering member 4095 label Biography information for Steve Barclay
tabling member	4433 label Biography information for Thangam Debbonaire

806629

registered interest
date	14/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Alcoholic Drinks: Minimum Unit Prices
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment his Department has made of the potential effect of minimum unit pricing on alcohol on reducing the incidence of cancer.
tabling member constituency	Bristol West
tabling member printed	Thangam Debbonaire
uin	119705
answer	answer is ministerial correction date of answer 21/12/2017 answer text <p>The Government has made no assessment of the potential effect of minimum unit pricing (MUP) of alcohol on reducing the incidence of cancer or the number of cancer deaths. MUP and its effects will continue to remain under review pending the impact of its implementation in Scotland.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 119707 question first answered 21/12/2017 16:27:03 answering member 4067 label Biography information for Steve Brine
tabling member	4433 label Biography information for Thangam Debbonaire

806631

registered interest
date	14/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Alcoholic Drinks: Minimum Unit Prices
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment his Department has made of the effect of minimum unit pricing of alcohol on the number of cancer deaths.
tabling member constituency	Bristol West
tabling member printed	Thangam Debbonaire
uin	119707
answer	answer is ministerial correction date of answer 21/12/2017 answer text <p>The Government has made no assessment of the potential effect of minimum unit pricing (MUP) of alcohol on reducing the incidence of cancer or the number of cancer deaths. MUP and its effects will continue to remain under review pending the impact of its implementation in Scotland.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 119705 question first answered 21/12/2017 16:27:04 answering member 4067 label Biography information for Steve Brine
tabling member	4433 label Biography information for Thangam Debbonaire

805975

registered interest
date	13/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Clinical Trials
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment his Department has made of whether the UK not being part of the Clinical Trials Regulation coming into effect in 2019 will be able to take part in such trials after the UK leaves the EU.
tabling member constituency	Bristol West
tabling member printed	Thangam Debbonaire
uin	119185
answer	answer is ministerial correction date of answer 21/12/2017 answer text <p>The Government values the strong collaborative partnerships that we have across the European Union in the areas of science, research and innovation, and as part of Exit negotiations is working to ensure that we have the best possible environment in which to support clinical trials and new medicines after we leave the EU.</p><p> </p><p>In the United Kingdom, the Medicines and Healthcare products Regulatory Agency, Health Research Authority, ethics services, National Institute for Health Research and National Health Service have been working towards implementation of the new European Clinical Trials Regulation (CTR) since it was agreed in 2014. The application date of the CTR across the EU will be set by the European Commission. The current regulatory approval legislation will stay in place until such time as any changes are needed so there will be no interruption in UK clinical trials approval.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 119186 question first answered 21/12/2017 17:02:31 answering member 4067 label Biography information for Steve Brine
tabling member	4433 label Biography information for Thangam Debbonaire

805976

registered interest
date	13/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Clinical Trials: EU Law
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment his Department has made of the legislation that will be required in the UK to ensure that the UK becomes compatible with the EU Clinical Trials Regulation coming into force in 2019.
tabling member constituency	Bristol West
tabling member printed	Thangam Debbonaire
uin	119186
answer	answer is ministerial correction date of answer 21/12/2017 answer text <p>The Government values the strong collaborative partnerships that we have across the European Union in the areas of science, research and innovation, and as part of Exit negotiations is working to ensure that we have the best possible environment in which to support clinical trials and new medicines after we leave the EU.</p><p> </p><p>In the United Kingdom, the Medicines and Healthcare products Regulatory Agency, Health Research Authority, ethics services, National Institute for Health Research and National Health Service have been working towards implementation of the new European Clinical Trials Regulation (CTR) since it was agreed in 2014. The application date of the CTR across the EU will be set by the European Commission. The current regulatory approval legislation will stay in place until such time as any changes are needed so there will be no interruption in UK clinical trials approval.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 119185 question first answered 21/12/2017 17:02:31 answering member 4067 label Biography information for Steve Brine
tabling member	4433 label Biography information for Thangam Debbonaire

805102

registered interest
date	12/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Rare Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health what steps his Department is taking to ensure that researchers in the UK can continue to access pan-EU patient cohorts for rare disease and other special populations after the UK has withdrawn from the EU; and if he will make a statement.
tabling member constituency	Bristol West
tabling member printed	Thangam Debbonaire
uin	118774
answer	answer is ministerial correction date of answer 20/12/2017 answer text <p>The Government's policy paper, Collaboration on Science and Innovation: A Future Partnership Paper, emphasises the importance of continued collaboration with European partners to ensure that the United Kingdom remains one of the best places in the world for science and innovation. European Reference Networks for rare diseases were cited in the paper as an example of a partnership that the UK believes should continue.</p><p> </p><p>A key principle for the Government is that patients should not be put at a disadvantage as a result of European Union-exit.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 20/12/2017 11:50:56 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4433 label Biography information for Thangam Debbonaire